<p>Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer.</p>.<p>The Food and Drug Administration gave accelerated approval to Jaypirca for the treatment of adults mantle cell lymphoma after at least two lines of therapy.</p>.<p>The approval is based on data from a subset of patients from early- to mid-stage trials. The confirmatory late-stage trial is currently enrolling patients, the U.S. drugmaker added.</p>.<p>The drug is expected to be available in the United States in the coming weeks, the company said.</p>
<p>Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer.</p>.<p>The Food and Drug Administration gave accelerated approval to Jaypirca for the treatment of adults mantle cell lymphoma after at least two lines of therapy.</p>.<p>The approval is based on data from a subset of patients from early- to mid-stage trials. The confirmatory late-stage trial is currently enrolling patients, the U.S. drugmaker added.</p>.<p>The drug is expected to be available in the United States in the coming weeks, the company said.</p>